All News

infx.pneumonia.jpg

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

Jack Cush, MD

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

Read Article
RN.Laptop.jpg

ACR 2020 Your Way - Get Your Topic Emails

Jack Cush, MD

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

Read Article
moneyglobe.jpg

US Differs from Worldwide Drug Reimbursements

Jack Cush, MD

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine.  US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

Read Article
podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
colitis.jpg

Vedolizumab Promising in Immune-Related GI Events

Jack Cush, MD

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Read Article
Telemedicine.MD.Computer.phone (keep)

Telemedicine Outcomes in RA Care

Jack Cush, MD

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

Read Article
podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
depression oh no HA

Biologic Use for Arthritis Linked With Depression and Anxiety

Jack Cush, MD

In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.

Read Article
Eosinophilia in #RA is either due to a secondary problem (endemic parasitosis, drug hypersensitivity, etc) or may be associated with more severe RA - it is not associated with extraarticular manifestations of RA. https://t.co/J9rOA3cWC4

Links:

Dr. John Cush RheumNow ( View Tweet)

Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital (OR=2.7, 1.7, 2.7) https://t.co/OGmarAfzLM

Links:

Dr. John Cush RheumNow ( View Tweet)

Metaanalysis of 7 cohort studies, 34 029 biologic & 135370 biologic-naive Pts (RA, PsO, IBD) looked at risk of melanoma (vs conventional Rx). Found no statistically significant increase risk for melanoma w/ biologics (eg RA RR 1.2; 95% CI, 0.83-1.74) https://t.co/rnZwzqE8m2

Links:

Dr. John Cush RheumNow ( View Tweet)

Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?

Links:

Peter Nash drpnash ( View Tweet)

New research shows potential utility of plasma specialized pro-resolving mediator (SPM; like RvD4, 10S, 17S-diHDPA, 15R-LXA4 and MaR1n-3 DPA) concentrations as biomarkers to predict DMARD responsiveness in #RA. https://t.co/WQb57EON10

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)

Dr. John Cush RheumNow ( View Tweet)

PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA

Links:

Dr. John Cush RheumNow ( View Tweet)

Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful iTunes https://t.co/FHJv01Sb3a SoundCloud https://t.co/fceBeXGu09

Links:

Dr. John Cush RheumNow ( View Tweet)

Korea National Health databased looked at Fracture rates in RA patients taking TNFis, abatacept, or tocilizumab betw 2002 to 2016. They found no difference in Fx risk related to the biologic taken. https://t.co/W2dWWseXTc

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of seropositivity in RA patients in the RISE (43,581) registry & Marketscan pts (1185) showed ICD10 Coding with M05 had a sensitivity = 0.73- 0.76, & PPV = 0.82 -0.84 for seropositive RA. Good but does that mean Ya'll are miscoding 25% of your RA pts?https://t.co/Wc6FQeQEHA

Links:

Dr. John Cush RheumNow ( View Tweet)

SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?

Dr. John Cush RheumNow ( View Tweet)

QD Clinics - Vignette Lessons from Rheum Clinic. Week 2: choosing IL-1 inhibitors, burnt out RA or not RA, trigger fingers, peripheral SpA, Gout or not? Listen on iTunes https://t.co/FHJv01Sb3a or on Android https://t.co/V488PY9lIo

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×